



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DLI978PLC009181

Date: August 13th, 2019

To, The Department of Corporate Services- Listing Bombay Stock Exchange Ltd, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001	To, National Stock Exchange of India Ltd. Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
Scrip Code: 507789	Symbol: JAGSNPHARM

**SUB: SUBMISSION OF STANDALONE UN-AUDITED FINANCIAL RESULTS
ALONG WITH LIMITED REVIEW REPORT FOR THE QUARTER ENDED 30TH
JUNE, 2019.**

Dear Sir,


In terms of the provisions of Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Standalone Un-Audited Financial Results for the Quarter ended 30th June, 2019 duly approved by the Board at its meeting held on 13th August, 2019.

The Limited Review Report on the Standalone Un-Audited Financial Results for the Quarter 30th June, 2019 in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015 is also enclosed herewith.


Kindly take the above on record & oblige.

Thanking You,

For JAGSONPAL PHARMACEUTICALS LIMITED


R K Kapoor

Company Secretary cum Compliance Officer





JAGSONPAL PHARMACEUTICALS LIMITED

20, K.M. Mathura Raod, P.O. Amar Nagar, Faridabad - 121003
Phone : 0129-2275952-53, 0129-2275653, Fax No. 0129-2278531

Statement of Standalone Unaudited Financial Results for the Quarter ended 30.06.2019

Rs. in lacs

Particulars	Standalone		12 Months	
	Quarter Ended		Year Ended	
	30.06.2019	31.03.2019	30.06.2018	31.03.2019
	Unaudited	Audited	Unaudited	Audited
1 Income from operations				
a Gross Sales/Revenue from Operations	4523.40	3840.22	4240.40	16682.56
b Other Operating Income	0.00	0.00	0.00	0.00
Total Income from operations	4523.40	3840.22	4240.40	16682.56
2 Other Income	67.12	87.95	8.79	142.90
3 Total Income [1+2]	4590.52	3928.17	4249.19	16825.46
4 Expenses				
a Cost of materials consumed	1173.13	746.34	850.56	3878.66
b Purchases of stock-in-trade	474.83	539.39	316.36	1464.08
c Changes in inventories of finished goods, work in progress and Stock in trade	201.11	101.19	968.37	1941.82
d Excise Duty	0.00	0.00	0.00	0.00
e Employee benefits expenses	1314.51	1059.88	1062.42	4661.1
f Finance Cost	11.77	27.31	17.08	74.55
g Depreciation and amortisation expense	28.61	28.13	25.40	101.58
h Other expenses	1136.10	1052.23	918.09	3803.39
Total expenses	4340.06	3554.47	4158.28	15925.18
5 Profit before exceptional items and taxes (3-4)	250.46	373.70	90.91	900.28
6 Exceptional Items	0.00	0.00	0.00	0.00
7 Profit before tax [5-6]	250.46	373.70	90.91	900.28
8 Tax expense	50.09	76.24	18.18	178.67
9 Net Profit for the period [7-8]	200.37	297.46	72.73	721.61
10 Other Comprehensive Income				
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
11 Total Other Comprehensive Income [A(i) + A(ii)]	0.00	0.00	0.00	0.00
12 Total Comprehensive Income [9+11]	200.37	297.46	72.73	721.61
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90
14 Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)				
a. Basic (Rs.)	0.76	1.14	0.28	2.75
b. Diluted (Rs.)	0.76	1.14	0.28	2.75

Notes

- The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 13, 2019.
- In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
- The revenue for the quarter ended 30-6-2019, is reported net of GST.
- Provision for taxation includes provision for current tax.



Place : New Delhi
Date : 13-8-2019

For Jagsonpal Pharmaceuticals Limited
By Order of the Board
For Jagsonpal Pharmaceuticals Limited
Rajpal Singh Kochhar
Mg. Director

Rajpal Singh Kochhar
Managing Director
DIN No 00059492



LIMITED REVIEW REPORT

The Board of Directors
Jagsonpal Pharmaceuticals Limited
T-210-J, Shahpur Jat
New Delhi-110049

1. We have reviewed the Unaudited Financial Results of Jagsonpal Pharmaceuticals Limited (the "Company") for the Quarter ended 30th June, 2019 which are included in the accompanying Statement of Standalone Financial Results for the Quarter ended 30th June, 2019 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") and SEBI Circular dated July 5, 2016, which has been initialed by us for identification purposes.
2. The Statement is the responsibility of the Company's management and is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent and are in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with IND AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing regulations, 2015 and SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not qualified in respect of these matters.

Date: 13 August, 2019
Place: New Delhi

For H.L. Bansal & Co.
Firm Registration Number: 08563N
Chartered Accountants

H. L. Bansal
Proprietor
Membership Number 086990
UDIN: 19086990AAAACF5020

